These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35103292)

  • 1. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
    Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
    Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
    PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
    Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
    Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target.
    Liu L; Zhang J; Zhang X; Cheng P; Liu L; Huang Q; Liu H; Ren S; Wei P; Wang C; Dou C; Chen L; Liu X; Zhang H; Chen M
    J Mol Med (Berl); 2021 Jan; 99(1):107-118. PubMed ID: 33128580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
    Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
    J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
    Li Y; Chen K; Zhou Y; Xiao Y; Deng M; Jiang Z; Ye W; Wang X; Wei X; Li J; Liang J; Zheng Z; Yao Y; Wang W; Li P; Xu B
    Curr Cancer Drug Targets; 2015; 15(6):493-503. PubMed ID: 26282548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both
    Li J; Liao D; Wang F; Wang Z; Li Y; Xiong Y; Niu T
    Leuk Lymphoma; 2022 May; 63(5):1167-1179. PubMed ID: 34865571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide inhibits cell glycolysis in acute myeloid leukemia by decreasing N6-methyladenosine-related GNAS-AS1.
    Hu C; Fu X; Li S; Chen C; Zhao X; Peng J
    Daru; 2024 Jun; 32(1):11-24. PubMed ID: 37926762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
    Wang H; Liu YC; Zhu CY; Yan F; Wang MZ; Chen XS; Wang XK; Pang BX; Li YH; Liu DH; Gao CJ; Liu SJ; Dou LP
    J Exp Clin Cancer Res; 2020 Dec; 39(1):278. PubMed ID: 33298132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports.
    Wang BR; Wan CL; Liu SB; Qiu QC; Wu TM; Wang J; Li YY; Ge SS; Qiu Y; Shen XD; Xue SL; Li Z
    Front Oncol; 2021; 11():797941. PubMed ID: 34956909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells.
    Deng M; Xiao H; Peng H; Yuan H; Xiao X; Liu S
    Mol Cell Biochem; 2023 Apr; 478(4):851-860. PubMed ID: 36107284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
    Liu Z; Ding K; Li L; Liu H; Wang Y; Liu C; Fu R
    Biomed Pharmacother; 2016 Oct; 83():1032-1037. PubMed ID: 27541047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia.
    Chen K; Yang Q; Zha J; Deng M; Zhou Y; Fu G; Bi S; Feng L; Xu-Monette ZY; Chen XL; Fu G; Dai Y; Young KH; Xu B
    Cell Death Dis; 2020 Sep; 11(9):778. PubMed ID: 32948748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
    Li X; Yan X; Guo W; Huang X; Huang J; Yu M; Ma Z; Xu Y; Huang S; Li C; Zhou Y; Jin J
    Biomed Pharmacother; 2017 Jun; 90():699-704. PubMed ID: 28419965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
    Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
    Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
    Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.